<DOC>
	<DOCNO>NCT00994318</DOCNO>
	<brief_summary>Phase IIIb study evaluate long-term efficacy ferric carboxymaltose ( FCM ) ( use target ferritin level determine dose ) oral iron non-dialysis-dependent chronic kidney disease ( NDD-CKD ) subject iron deficiency anaemia ( IDA ) .</brief_summary>
	<brief_title>Ferric Carboxymaltose ( FCM ) Assessment Subjects With Iron Deficiency Anaemia Non-dialysis-dependent Chronic Kidney Disease ( NDD-CKD )</brief_title>
	<detailed_description>After initial screening period 4 week , eligible subject randomise ( 1:1:2 ) 1 follow 3 treatment arm period 52 week . 1 . FCM regimen ( maximum single intravenous dos 1,000 mg iron ) target ferritin level 400-600 mcg/L . 2 . FCM regimen ( maximum single intravenous dos 200 mg iron ) target ferritin level 100-200 mcg/L . 3 . Daily oral iron 200 mg iron/day ( 100 mg twice daily )</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . At least 18 year age . 2 . NDDCKD subject estimate glomerular filtration rate ( eGFR ) ≤60 mL/min/1.73 m2 use modification diet renal disease 4 ( MDRD4 ) calculation . 3 . NDDCKD subject eGFR loss ≤12 mL/min/1.73 m2/year predict eGFR ≥15 mL/min/1.73 m2 12 month . 4 . Any single Hb 9 11 g/dL within 4 week randomisation . A value take part routine medical care use . 5 . Any single serum ferritin &lt; 100 mcg/L &lt; 200 mcg/L TSAT &lt; 20 % within 4 week randomisation . Measurements take part routine medical care use . 6 . ESA naïve ; exposure ESA last 4 month prior randomisation . 7 . Females childbearing potential must negative pregnancy test , use medically acceptable assessment , prior randomisation . 8 . Before study specific procedure , appropriate write informed consent must obtain . 1 . History acquire iron overload . 2 . Known hypersensitivity reaction component ferrous sulphate FCM . Subjects hypersensitivity form iron permitted participate . 3 . Documented history discontinue oral iron product due significant gastrointestinal ( GI ) distress . 4 . Screening TSAT &gt; 40 % . 5 . Known active infection , Creactive protein &gt; 20 mg/L , clinically significant overt bleeding , active malignancy ( i.e. , clinical evidence current malignancy stable remission least 5 year since completion last treatment exception basal cell squamous cell carcinoma skin , cervical intraepithelial neoplasia ) . 6 . History chronic alcohol abuse ( alcohol consumption &gt; 40 g/day ) . 7 . Chronic liver disease and/or screen alanine transaminase aspartate transaminase 3 time upper limit normal range . 8 . Active human immunodeficiency virus ( HIV ) /acquired immunodeficiency syndrome active hepatitis B C virus infection . 9 . Anaemia due reason iron deficiency ( e.g. , haemoglobinopathy ) . Subjects treat Vitamin B12 folic acid deficiency permit . 10 . IV iron and/or blood transfusion previous 30 day prior screen ( screen period ) . 11 . Oral iron therapy dose &gt; 100 mg/day dose must discontinue least 1 week prior randomisation . If subject receive therapy &gt; 3 month ( dos &gt; 100 mg/day ) subject eligible . Ongoing use multivitamin contain iron permit . 12 . Immunosuppressive therapy may lead anaemia ( e.g. , cyclophosphamide , azathioprine , mycophenolate mofetil ) . Steroid therapy permit . 13 . Currently require renal dialysis . 14 . Anticipated dialysis transplant study . 15 . Anticipated need surgery may result significant bleeding ( &gt; 100 mL ) . 16 . Currently suffer chronic heart failure New York Heart Association Class IV . 17 . Poorly control hypertension ( &gt; 160 mmHg systolic pressure &gt; 100 mmHg diastolic pressure ) . 18 . Acute coronary syndrome stroke within 3 month prior screen . 19 . Currently suffer concomitant , severe psychiatric disorder condition , opinion Investigator , would make participation unacceptable . 20 . Subject use adequate contraceptive precaution . 21 . Subject childbearing potential evidently pregnant ( e.g. , positive human chorionic gonadotropin test ) breast feeding . 22 . Body weight &lt; 35 kg . 23 . Subject currently enrol yet complete least 30 day since end investigational device drug study , subject receive investigational agent ( ) . 24 . Subject would available followup assessment . 25 . Subject kind disorder compromise ability subject give write informed consent and/or comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Ferinject Iron Deficiency Anaemia Chronic Kidney Disease</keyword>
</DOC>